456 related articles for article (PubMed ID: 1734087)
1. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
[TBL] [Abstract][Full Text] [Related]
2. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
3. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
4. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
[TBL] [Abstract][Full Text] [Related]
6. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
7. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
8. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
[TBL] [Abstract][Full Text] [Related]
9. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
[TBL] [Abstract][Full Text] [Related]
11. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
[TBL] [Abstract][Full Text] [Related]
12. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.
Winick NJ; McKenna RW; Shuster JJ; Schneider NR; Borowitz MJ; Bowman WP; Jacaruso D; Kamen BA; Buchanan GR
J Clin Oncol; 1993 Feb; 11(2):209-17. PubMed ID: 8426196
[TBL] [Abstract][Full Text] [Related]
13. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood.
Maluf PT; Odone Filho V; Cristofani LM; Britto JL; Almeida MT; Pontes E; Maksoud JG; Manissadjian A
J Clin Oncol; 1994 Sep; 12(9):1963-8. PubMed ID: 8083717
[TBL] [Abstract][Full Text] [Related]
14. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
17. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
18. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
19. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.
Sullivan MP; Brecher M; Ramirez I; Ragab A; Hvizdala E; Pullen J; Shuster J; Berard C; Crist W; Vietti T
Am J Pediatr Hematol Oncol; 1991; 13(3):288-95. PubMed ID: 1793154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]